VANCOUVER, BRITISH COLUMBIA--(Marketwire - May 15, 2008) - Allon Therapeutics Inc. (TSX:NPC) The Neuro Protection CompanyTM, reported today in its First Quarter 2008 operating results that progress achieved during the quarter has kept the Company on a path to achieve its 2008 clinical development and financial milestones, including a development and commercialization partnership with a major pharmaceutical company. The Company's most significant achievement during the First Quarter was the release of top-line data February 26 demonstrating statistically significant human efficacy of its drug AL-108 in a Phase IIa clinical trial in patients with amnestic mild cognitive impairment (aMCI), a precursor to Alzheimer's disease (AD).
